Shenzhen - Delayed Quote CNY

Chengdu Kanghong Pharmaceutical Group Co., Ltd (002773.SZ)

Compare
22.80 -0.13 (-0.57%)
At close: 3:04 PM GMT+8
Loading Chart for 002773.SZ
DELL
  • Previous Close 22.93
  • Open 22.50
  • Bid 22.78 x --
  • Ask 22.80 x --
  • Day's Range 22.45 - 22.98
  • 52 Week Range 13.15 - 24.50
  • Volume 5,530,153
  • Avg. Volume 10,088,480
  • Market Cap (intraday) 21.083B
  • Beta (5Y Monthly) -0.03
  • PE Ratio (TTM) 18.39
  • EPS (TTM) 1.24
  • Earnings Date --
  • Forward Dividend & Yield 0.38 (1.66%)
  • Ex-Dividend Date May 28, 2024
  • 1y Target Est --

Chengdu Kanghong Pharmaceutical Group Co., Ltd research, develops, produces, and sells chemical drugs, chinese medicines, and biological products in China. It also develops ophthalmic medical devices. The company offers central nervous, digestive, and endocrine system drugs. Chengdu Kanghong Pharmaceuticals Group Co., Ltd. was founded in 1996 and is based in Chengdu, China.

www.cnkh.com

4,289

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002773.SZ

Performance Overview: 002773.SZ

Trailing total returns as of 6/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

002773.SZ
25.73%
SSE Composite Index
1.86%

1-Year Return

002773.SZ
21.39%
SSE Composite Index
7.43%

3-Year Return

002773.SZ
9.03%
SSE Composite Index
14.05%

5-Year Return

002773.SZ
30.95%
SSE Composite Index
4.94%

Compare To: 002773.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002773.SZ

Valuation Measures

Annual
As of 6/17/2024
  • Market Cap

    21.08B

  • Enterprise Value

    16.02B

  • Trailing P/E

    18.34

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.02

  • Price/Book (mrq)

    2.58

  • Enterprise Value/Revenue

    3.85

  • Enterprise Value/EBITDA

    12.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    27.34%

  • Return on Assets (ttm)

    8.93%

  • Return on Equity (ttm)

    14.65%

  • Revenue (ttm)

    4.17B

  • Net Income Avi to Common (ttm)

    1.14B

  • Diluted EPS (ttm)

    1.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.06B

  • Total Debt/Equity (mrq)

    0.02%

  • Levered Free Cash Flow (ttm)

    837.43M

Research Analysis: 002773.SZ

Company Insights: 002773.SZ

Research Reports: 002773.SZ

People Also Watch